Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

BACKGROUND: Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle. The known triggers for complement activation can be diverse an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thromb J
Hlavní autoři: Hanna, Ramy M., Merin, Noah, Burwick, Richard M., Abdelnour, Lama, Selamet, Umut, Yanny, Beshoy, Bui, Patrick, Fouad, Mary, Kurtz, Ira
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6732828/
https://ncbi.nlm.nih.gov/pubmed/31516395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-019-0207-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky